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While clinical and pathologic responses are important prognostic parameters,  biological markers from 
core needle biopsy (CNB) are needed to predict neoadjuvant chemotherapy (NAC) response,  to indi-
vidualize treatment,  and to achieve maximal eﬃcacy.  We retrospectively evaluated the cases of 183 
patients with primary breast cancer who underwent surgery after NAC (anthracycline and taxane) at 
the National Cancer Center Hospital (NCCH).  We analyzed EGFR,  HER2,  and p53 expression and 
common clinicopathological features from the CNB and surgical specimens of these patients.  These 
biological markers were compared between sensitive patients (pathological complete response; pCR) 
and insensitive patients (clinical no change; cNC and clinical progressinve disease; cPD).  In a com-
parison between the 9 (5ｵ) sensitive patients and 30 (16ｵ) insensitive patients,  overexpression of p53 
but not overexpression of either HER2 or EGFR was associated with a good response to NAC.  p53 (p
＝0.045) and histological grade 3 (p＝0.011) were important and signiﬁcant predictors of the response 
to NAC.  The correspondence rates for histological type,  histological grade 3,  ER,  PgR,  HER2,  p53,  
and EGFR in insensitive patients between CNB and surgical specimens were 70ｵ,  73ｵ,  67ｵ,  70ｵ,  
80ｵ,  93ｵ,  and 73ｵ.  The pathologic response was signiﬁcantly associated with p53 expression and 
histological grade 3.  The correspondence rate of p53 expression between CNB and surgical specimens 
was higher than that of other factors.  We conclude that the level of p53 expression in the CNB was an 
eﬀective and reliable predictor of treatment response to NAC.
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eoadjuvant chemotherapy (NAC) is the standard 
therapy for patients with advanced local breast 
cancer and is used increasingly for operable disease.  
Clinical and pathologic responses are important prog-
nostic parameters,  but cannot be accurately predicted.  
Unfortunately,  approximately 20ｵ of breast cancer 
patients do not beneﬁt from NAC (i.e.,  they continue 
to show stable or progressive disease).  One of the 
aims of NAC is to conﬁrm the sensitivity of tumors to 
chemotherapy.  Using NAC,  we can directly deter-
mine the sensitivity to chemotherapy based on whether 
or not the primary tumor is diminished,  whereas we 
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cannot conﬁrm the eﬃcacy by adjuvant chemotherapy 
itself.  However,  non-sensitive patients have to endure 
relatively needless therapy for about 6 months,  so it 
is very important to make the pre-diagnosis of sensi-
tivity to chemotherapy if possible.  Several biological 
markers that might predict response are under inves-
tigation [1-9].  Estrogen receptor,  progesterone 
receptor,  and HER2 are very useful markers for the 
selection of anticancer drugs and prediction of progno-
sis,  but are not useful for predicting the response to 
chemotherapeutic agents such as anthracycline and 
taxane.  Therefore,  other biological markers from pre-
treatment core needle biopsy are needed to predict the 
response to NAC,  to individualize treatment,  and to 
achieve maximal eﬃcacy.
　 In this study,  we investigated biological markers 
from pre-treatment core needle biopsies of highly 
sensitive tumors and non-sensitive tumors and identi-
ﬁed additional prognostic markers that might predict 
the response to NAC and aid in the selection of treat-
ment strategy.
Materials and Methods
　 All patients with operable breast cancer who were 
treated between May 1998 and July 2006 at the 
National Cancer Center Hospital with anthracycline 
and/or taxane as NAC were included in this retro-
spective study.  NAC was indicated for clinical stage 
II breast cancer patients with tumors larger than 3cm 
and stage III breast cancer patients.  Core needle 
biopsy was performed before NAC to allow pathologi-
cal diagnosis.  Doxorubicin (DOX,  50mg/m2) and 
docetaxel (DTX,  60mg/m2) were administered for 
four 3-week cycles before surgery.  Additional adju-
vant treatment with DOX/DTX was given if patients 
achieved complete or partial remission after NAC.  
Otherwise,  patients were treated with four cycles of 
iv cyclophosphamide,  methotrexate,  and 5FU.  
Trastuzumab was not administered to the patients with 
HER2-overexpressing tumors.  Tamoxifen (20mg/day) 
or anastrozole (10mg/day) was administered for 5 
years after surgery if either the pretreatment biopsy 
specimen or the surgical specimen post-chemotherapy 
was positive for estrogen-receptor or progesterone 
receptor.
　 Pretreatment diagnosis was established by our 
pathologists using samples from core needle biopsy or 
surgical resection.  Overexpression of hormone recep-
tors,  p53,  HER2 and EGFR was examined by immu-
nohistology.  Surgical specimens were sectioned at 
about 7-10mm and classiﬁed for pathological 
response.  Pathological features were described and 
invasive ductal carcinomas were classiﬁed into 3 sub-
types (papillotubular,  solid tubular,  and scirrhous) 
according to the General and Pathological Recording 
of Breast Cancer guidelines established by the 
Japanese Breast Cancer Society [10].  The criteria 
for histological grading of IDC were based on a modi-
ﬁcation of those recommended by the WHO [11,  12].  
The response criteria used in this study include 
Fisherʼs system [13],  complete pCR denotes no his-
tological evidence of tumor cells,  pCR with DCIS 
denotes no histological evidence of invasive tumor 
cells (specimens with only noninvasive cells included),  
and pINV denotes the presence of invasive tumor cells.  
Overexpression of ER (1D5,  Dako Cytomation,  
Baltimore,  MD,  USA),  PgR (1A6,  Novocastra),  HER2 
(Herceptest,  Dako),  p53 (DO7,  Dako),  and EGFR 
(2-18C9,  Dako) were examined by immunohistology 
using the noted antibodies.  The criterion for ER,  
PgR,  and p53 was staining of more than 10ｵ of can-
cer cell nuclei,  regardless of intensity.  HER2 and 
EGFR grading is as follows: 0: negative,  1＋: slightly 
positive in more than 10ｵ of cancer cells,  2＋: mod-
erately positive in more than 10ｵ of cancer cells,  
3＋: markedly positive in more than 10ｵ of cancer 
cells.  2＋ and 3＋ were considered positive for HER2 
and EGFR.
　 Clinical response to NAC was decided from the 2 
greatest perpendicular diameters (before each chemo-
therapy treatment and before surgery) of tumors in the 
breast and axillary lymph nodes.  Absence of clinical 
evidence of palpable tumors in the breast and axillary 
lymph nodes was deﬁned as a clinical complete 
response (cCR).  Reduction in total tumor size of 
30ｵ or greater was graded as clinical partial 
response (cPR).  An increase in total tumor size of 
more than 20ｵ or appearance of new suspicious ipsi-
lateral axillary adenopathy was considered progres-
sive disease (cPD).  Tumors that did not meet the 
criteria for objective response or progression were 
classiﬁed as stable disease (cSD).  In this study,  we 
analyzed biological markers from core needle biopsies 
before NAC in complete pCR cases and non-sensitive 
tumors (clinical SD and PD),  and demonstrated bio-
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logical predictors of pathological response to PST.
　 Statistical analysis was carried out using JMP 
version 6.0 (SAS Institute Inc.,  Cary,  NC,  USA).  
Associations between ordinal variables were assessed 
using χ2 analyses or the Fisher exact test for two-by-
two variables.  The statistical signiﬁcance (P) was 
taken as a measure of the strength of evidence against 
the null hypothesis,  and pｦ .05 was considered statis-
tically signiﬁcant.
Results
　 One hundred and eighty-three patients with opera-
ble breast cancer were treated with NAC at National 
Cancer Center Hospital between May 1998 and 
October 2001.  Table 1 lists the patient and tumor 
characteristics.  The median age was 50 years (range:  
29-70).  At diagnosis,  41 (22ｵ) patients were in stage 
IIA,  63 (34ｵ) were in stage IIB,  37 (20ｵ) were in 
stage IIIA,  and 42 (23ｵ) were in stage IIIB.  Breast 
conserving surgery was performed for 55 (30ｵ) 
patients after NAC.  The overall clinical response rate 
to NAC was 83ｵ (cCR＋cPR) and the pCR rate was 
13ｵ.  30 (17ｵ) patients were insensitive to NAC 
(cSD or cPD).  Among the responsive patients,  9 (5ｵ) 
exhibited complete pCR (pathologically no tumor in the 
breast) and 14 (8ｵ) exhibited pCR with DCIS.
　 Immunohistological characteristics from core nee-
dle biopsy before NAC are listed in Table 2.  There 
were 62 (34ｵ) cases of solid tubular primary tumor,  
65 (36ｵ) scirrhous,  34 (19ｵ) papillotubular,  9 (5ｵ) 
ILC,  and 3 (2ｵ) mucinous carcinomas.  88 (48ｵ) 
cases were histological grade 3.  66 (36ｵ) were ER 
positive and 72 (39ｵ) were PgR positive.  73 (40ｵ) 
were HER-2 positive (2＋ and 3＋ in immunohistologi-
cal examination).
　 We evaluated age,  histological type,  histological 
grade,  ER,  PgR,  HER2,  EGFR,  and p53 as predic-
tive factors for response to NAC by comparing 
9 (5ｵ) sensitive (complete pCR) and 30 (17ｵ) insen-
sitive (cSD and cPD) tumors (Table 3).  In univariate 
analysis,  histological grade 3 (p＝0.011) and p53 
(p＝0.045) were signiﬁcant predictors of complete 
pCR.  However,  EGFR and HER2 were not predic-
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Table 1　 Patient and tumor characteristics
Parameter No. of patients (%)
Total 183 　
Age (median) 50 (29-70)
Clinical stage
　　Stage IIA 41 (22%)
　　Stage IIB 63 (34%)
　　Stage IIIA 37 (20%)
　　Stage IIIB　 42 (23%)
Operation
　　Bt＋Ax 128 (70%)
　　Bp＋Ax 55 (30%)
Clinical response
　　cCR　 32 (17%)
　　cPR 121 (66%)
　　cNC 29 (16%)
　　cPD 1 (1%)
Pathological response
　　complete pCR 9 (5%)
　　pCR with DCIS 14 (8%)
　　pINV　 160 (87%)
Bt,  total mastectomy; Bp,  partial mastectomy; Ax,  axillary lymph 
node dissection.
Table 2　 Immunohistological characteristics of CNB before PST
Parameter No. of patients (%)
Histological type
IDC 161 (88)
　　Solid tubular 62 (34)
　　Scirrhous 65 (36)
　　Papillotubular 34 (19)
ILC 9 (5)
mucinous 3 (2)
others 10 (5)
Histological grade
　　3 88 (48)
　　2 88 (48)
　　1 7 (4)
ER
　　positive 66 (36)
　　negative 117 (64)
PgR
　　positive 72 (39)
　　negative 111 (61)
HER2
　　positive (2＋and 3＋ ) 73 (40)
tors.
　 We analyzed the immunohistological features of 
CNB specimens.  The correspondence rates of these 
features in insensitive patients between CNB and 
surgical specimens are shown in Table 4.  The corre-
spondence rates for histological type,  histological 
grade 3,  ER,  PgR,  HER2,  p53,  and EGFR were 
70ｵ,  73ｵ,  67ｵ,  70ｵ,  80ｵ,  93ｵ,  and 73ｵ.  
The correspondence rate of EGFR was not low;  
however,  in almost all patients with a discrepancy 
between CNB and surgical specimens,  EGFR overex-
pression changed from negative to positive.
Discussion
　 The identiﬁcation of predictive factors for NAC is 
very important for order made cancer treatment.  The 
development of new medicines has diversiﬁed chemo-
therapeutic regimens,  and the selection of treatment 
strategy according to individual cancer characteristics 
has become more diﬃcult.  To aid in selection,  trans-
lational research has begun to demonstrate important 
correlations between prognostic factors and sensitiv-
ity to chemotherapy.
　 In this study,  we retrospectively evaluated response 
to NAC including anthracycline and taxane and a 
number of biomarkers.  We found that pathologic 
response signiﬁcantly associated with p53 expression 
and histological grade 3.
　 In our analysis,  p53 could predict response of 
NAC.  p53 accumulation was reported to be associ-
ated with a poor response to anthracycline in node-
negative breast cancer patients [14],  and may com-
promise the eﬃcacy of anthracycline but not of taxane 
[15].  All patients in this study received both anthra-
cycline and taxane,  and p53 was an independent pre-
dictive factor of response to NAC similar to these 
reports.  We cannot analyze the response of anthracy-
cline and taxane respectively.  However commonly we 
use both drugs in NAC.  If the tumor has p53 mutation 
before NAC,  we should check the response of anthra-
cycline tightly and change to taxane when the response 
is wrong.
　 Previous studies reported poor prognosis for 
patients with HER2-overexpression.  Several studies 
indicate that HER2 expression can predict sensitivity 
to anthracycline chemotherapy [16]; however,  in this 
study,  HER2 was not a predictor of pCR to NAC.  
HER2 negative patients rate were 22ｵ of good 
responders and 33ｵ of poor responders.  In this study 
trastuzumab was not administered to patients with 
HER2 overexpression tumors.  However,  in these 
days,  trastuzumab signiﬁcantly improved the progno-
sis and the response to chemotherapy in these patients 
[17].  It was reported that the rate of pCR patients 
administered trastuzumab was signiﬁcantly high.  HER2 
expression was not predictor of response to anthracy-
cline and taxane in this study.  We need to examine the 
relationship between HER2-overexpression and 
response to chemotherapy with trastuzumab.
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Table 3　 Univariate analysis of clinicopathological features between sensitive (pCR) and insensitive cases (cNC ＋ cPD)
Parameter Sensitive (n＝9) (%) Non-sensitive (n＝30) (%) p-value
Age＜50 3 (33) 19 (63) N.S.
Histological type (so.) 6 (67) 12 (40) N.S.
Histological grade 3 8 (89) 13 (43) 0.011
ER negative 8 (89) 17 (57) N.S.
PgR negative 6 (67) 17 (57) N.S.
HER2 positive 2 (22) 10 (33) N.S.
p53 positive 5 (56) 6 (20) 0.045
EGFR positive 3 (33) 7 (23) N.S.
so,  solid tubular carcinoma
Table 4　 Correspondence rates of biological markers in insensi-
tive patients between CNB and surgical specimens
Parameter %
Histological type 70
Histological grade 3 73
ER 67
PgR 70
HER2 80
p53 93
EGFR 73
　 A previous study observed EGFR expression in 
37-80ｵ of basal-like tumors,  as identiﬁed by DNA 
microarray,  and reported poorer prognosis for this 
phenotype [18-20].  We hypothesized that EGFR 
expression might distinguish the basal-like phenotype 
and predict poorer response to NAC.  However,  in 
this study,  EGFR was not an independent predictive 
factor of response to NAC.  It was reported that 
EGFR is expressed in 7-36ｵ of breast carcinomas 
with high grade conventional invasive ductal carci-
noma (IDC) [21-24] and EGFR expression was seen 
in 272 (20ｵ) of 1388 cases.  In a univariate analysis,  
Tsutsui et al.  showed a signiﬁcantly poorer clinical 
outcome for patients with EGFR-positive tumors 
compared with those who were EGFR-negative,  both 
for overall survival and disease-free survival [21].  
The correspondence rate of EGFR overexpression 
between core needle biopsy and surgical specimens 
was higher than the correspondence rates of common 
predictive factors (ER,  PgR,  and HER2) between the 
2 types of specimens.  However,  the rates of EGFR 
expression were relatively low in both sensitive (33ｵ) 
and insensitive patients (23ｵ).  In addition,  in cases 
in which EGFR expression did not correspond 
between CNB and surgical specimens,  EGFR was 
always negative in CNB,  but positive in the surgical 
specimen.  Therefore,  it is possible that core needle 
biopsy specimens are inadequate to evaluate EGFR 
overexpression,  or that EGFR expression was stimu-
lated by chemotherapy.  Following NAC,  highly 
malignant EGFR-positive tumor cells increased in 
number,  while EGFR-negative cells decreased in 
number.  In these specimens,  other common predictive 
factors did not change pre- and post-NAC; therefore 
it is not certain that all of the CNB specimens were 
inadequate.  Indeed,  it may be that NAC changed the 
characteristics of some tumors.
　 We evaluated EGFR,  HER2,  p53 and other com-
mon markers in specimens from pretreatment core 
needle biopsies as predictors of response to NAC.  p53 
was a more signiﬁcant predictor than ER and histo-
logical grade,  factors that have been previously 
reported.  These results may have been inﬂuenced by 
the uncertainty of core needle biopsy results and the 
heterogeneity of cancer cells in the tumors.  The cor-
respondence rates of these common markers between 
CNB and surgical specimens were relatively low.  
However,  the correspondence rate of p53 was signiﬁ-
cantly high.  This result indicates that p53 is a stable 
parameter and suitable for predicting the response to 
neoadjuvant chemotherapy and for pretreatment diag-
nosis from CNB specimens.
　 Pretreatment diagnosis from CNB specimens is 
necessary to decide the strategy for primary breast 
cancer treatment.  Therefore,  identifying prognostic 
factors is very important,  and we need a greater 
sample size to establish a classiﬁcation system to 
predict patient outcome.
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